Literature DB >> 20445019

The inositol phosphatase SHIP-1 is negatively regulated by Fli-1 and its loss accelerates leukemogenesis.

Gurpreet K Lakhanpal1, Laura M Vecchiarelli-Federico, You-Jun Li, Jiu-Wei Cui, Monica L Bailey, David E Spaner, Daniel J Dumont, Dwayne L Barber, Yaacov Ben-David.   

Abstract

The activation of Fli-1, an Ets transcription factor, is the critical genetic event in Friend murine leukemia virus (F-MuLV)-induced erythroleukemia. Fli-1 overexpression leads to erythropoietin-dependent erythroblast proliferation, enhanced survival, and inhibition of terminal differentiation, through activation of the Ras pathway. However, the mechanism by which Fli-1 activates this signal transduction pathway has yet to be identified. Down-regulation of the Src homology 2 (SH2) domain-containing inositol-5-phosphatase-1 (SHIP-1) is associated with erythropoietin-stimulated erythroleukemic cells and correlates with increased proliferation of transformed cells. In this study, we have shown that F-MuLV-infected SHIP-1 knockout mice display accelerated erythroleukemia progression. In addition, RNA interference (RNAi)-mediated suppression of SHIP-1 in erythroleukemia cells activates the phosphatidylinositol 3-kinase (PI 3-K) and extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK) pathways, blocks erythroid differentiation, accelerates erythropoietin-induced proliferation, and leads to PI 3-K-dependent Fli-1 up-regulation. Chromatin immunoprecipitation and luciferase assays confirmed that Fli-1 binds directly to an Ets DNA binding site within the SHIP-1 promoter and suppresses SHIP-1 transcription. These data provide evidence to suggest that SHIP-1 is a direct Fli-1 target, SHIP-1 and Fli-1 regulate each other in a negative feedback loop, and the suppression of SHIP-1 by Fli-1 plays an important role in the transformation of erythroid progenitors by F-MuLV.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20445019     DOI: 10.1182/blood-2009-10-250217

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  25 in total

1.  Therapeutic potential of SH2 domain-containing inositol-5'-phosphatase 1 (SHIP1) and SHIP2 inhibition in cancer.

Authors:  Gwenny M Fuhler; Robert Brooks; Bonnie Toms; Sonia Iyer; Elizabeth A Gengo; Mi-Young Park; Matthew Gumbleton; Dennis R Viernes; John D Chisholm; William G Kerr
Journal:  Mol Med       Date:  2012-02-10       Impact factor: 6.354

2.  Abnormal expression of FLI1 protein is an adverse prognostic factor in acute myeloid leukemia.

Authors:  Steven M Kornblau; Yi Hua Qiu; Nianxiang Zhang; Neera Singh; Stefan Faderl; Alessandra Ferrajoli; Heather York; Amina A Qutub; Kevin R Coombes; Dennis K Watson
Journal:  Blood       Date:  2011-09-13       Impact factor: 22.113

3.  Protein kinase C δ deficiency enhances megakaryopoiesis and recovery from thrombocytopenia.

Authors:  John C Kostyak; Dheeraj Bhavanasi; Elisabeta Liverani; Steven E McKenzie; Satya P Kunapuli
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-10-30       Impact factor: 8.311

4.  B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies.

Authors:  Gang Xiao; Lai N Chan; Lars Klemm; Daniel Braas; Zhengshan Chen; Huimin Geng; Qiuyi Chen Zhang; Ali Aghajanirefah; Kadriye Nehir Cosgun; Teresa Sadras; Jaewoong Lee; Tamara Mirzapoiazova; Ravi Salgia; Thomas Ernst; Andreas Hochhaus; Hassan Jumaa; Xiaoyan Jiang; David M Weinstock; Thomas G Graeber; Markus Müschen
Journal:  Cell       Date:  2018-03-15       Impact factor: 41.582

5.  FLI1 Levels Impact CXCR3 Expression and Renal Infiltration of T Cells and Renal Glycosphingolipid Metabolism in the MRL/lpr Lupus Mouse Strain.

Authors:  Kamala P Sundararaj; Thirumagal Thiyagarajan; Ivan Molano; Fahmin Basher; Thomas W Powers; Richard R Drake; Tamara K Nowling
Journal:  J Immunol       Date:  2015-11-04       Impact factor: 5.422

Review 6.  Discovery and development of small molecule SHIP phosphatase modulators.

Authors:  William G Kerr; John D Chisholm; Dennis R Viernes; Lydia B Choi
Journal:  Med Res Rev       Date:  2013-12-02       Impact factor: 12.944

7.  Spi-1, Fli-1 and Fli-3 (miR-17-92) oncogenes contribute to a single oncogenic network controlling cell proliferation in friend erythroleukemia.

Authors:  Samer Kayali; Guillaume Giraud; François Morlé; Boris Guyot
Journal:  PLoS One       Date:  2012-10-08       Impact factor: 3.240

8.  A novel strategy for modulation of MDSC to enhance cancer immunotherapy.

Authors:  Tomar Ghansah
Journal:  Oncoimmunology       Date:  2012-09-01       Impact factor: 8.110

9.  Pharmacological targeting of phosphoinositide lipid kinases and phosphatases in the immune system: success, disappointment, and new opportunities.

Authors:  Matthew D Blunt; Stephen G Ward
Journal:  Front Immunol       Date:  2012-08-02       Impact factor: 7.561

10.  Drug-mediated inhibition of Fli-1 for the treatment of leukemia.

Authors:  Y-J Li; X Zhao; L M Vecchiarelli-Federico; Y Li; A Datti; Y Cheng; Y Ben-David
Journal:  Blood Cancer J       Date:  2012-01-27       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.